Last reviewed · How we verify
NCT04174066: BiobankSNI
From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP
trial testing blood sample in Nephrotic Syndrome in 144 participants. Status unknown.
20 May 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 144 |
| Start date | 20 May 2020 |
| Primary completion | 20 May 2021 |
| Estimated completion | 20 May 2025 |
| Sites | 2 locations across France |
Drugs / interventions tested
- blood sample — full drug profile →
- tissue sample — full drug profile →
- excreta
Conditions studied
- Nephrotic Syndrome — all drugs for Nephrotic Syndrome →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
12 Months and older, any sex, with Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Idiopathic Nephrotic Syndrome (INS) is a kidney disease characterized by massive proteinuria and hypoalbuminemia. It includes two anatomopathological entities: nephrotic syndrome with minimal glomerular lesions (SNLGM) and primary segmental and focal hyalinosis (PHF). Renal biopsy reveals a fusion of the feet of the podocytes without inflammatory lesions or deposits of immune complexes. Clinical and experimental observations strongly suggest that the immune system and podocyte dysfunction are the two facets of the disease. There are currently no clinical or biological markers to predict the diagnosis of corticosteroid sensitivity, corticosteroid dependence, or risk of recurrence of kidney disease after kidney transplantation. To our knowledge, no prospective studies have been designed to study both immune system alterations and podocyte damage as well as genetic predisposition variants in NIS. Therefore, the use of steroids/immunosuppressive agents is purely empirical with a multitude of side effects. The objective is to identify and test new therapeutic targets rather than conducting new trials with existing treatments, using either drug candidates or molecules selected by high throughput screening of libraries of repositioning molecules using an appropriate read-out. The biobank may also be used to analyze the effects of conventional treatments on identified new biomarkers. We expect the project to produce original and patentable results with subsequent valuation. Patentability will be anticipated before any publication on the subject. The patent and valorization cells of hospitals, INSERM and Universities will be involved in the results as soon as they are obtained.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Proteomics of Plasma and Plasma-Treated Podocytes: Application to Focal and Segmental Glomerulosclerosis.
Chhuon C, Herrera-Marcos LV, Zhang SY, Charrière-Bertrand C, et al · · 2023 · cited 5× · PMID 37569500 · DOI 10.3390/ijms241512124
Verify or expand the search:
- PubMed search for NCT04174066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sample
Trials testing the same drug.
- NCT07370792 — Contribution of Optical Genome Mapping (OGM) in the Diagnosis of Multiple Congenital Malformations With or Without Intel · NA · recruiting
- NCT07273331 — Nursing Needs of Patients With Cirrhosis · enrolling by invitation
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06968598 — Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models · NA · not yet recruiting
- NCT07332702 — Long Read Analysis in Spinal Muscular Atrophy - LOREASI · NA · recruiting
Other recruiting trials for Nephrotic Syndrome
Currently open trials in the same condition.
- NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
- NCT06635720 — REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) · Phase 3 · recruiting
- NCT06622915 — Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome · NA · recruiting
- NCT06161701 — Steroid Diabetes in Patients With Kidney Disease · recruiting
- NCT06373913 — The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom · recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04174066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04174066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing